Multi-modal treatment increases this risk more than monotherapy and the recommendation is to simplify treatment to monotherapy whenever possible. Methotrexate and 5-ASA appear to be safer agents than corticosteroids, anti-TNF and AZA/6-MP.188 Vaccination against opportunistic infections, such as HBV, varicella-zoster,
human papilloma virus, pneumococcus, and influenza virus, should be considered. Colonoscopy surveillance for colorectal cancer is recommended in patients with long-standing ulcerative colitis with the exception of proctitis. Level of agreement: a-60%, b-40%, c-0%, d-0%, e-0% Quality of evidence: selleckchem II-3 Classification of recommendation: C Current strategies in the reduction or management of colitis-associated CRC include chemoprophylaxis, colonoscopy surveillance of at-risk individuals and proctocolectomy, which is a potentially curative treatment for those with precancerous dysplasia or early cancer. Colonoscopy surveillance is recommended after 8–10 years of extensive colitis and 12–15 years of left-sided selleck compound colitis.189 The detection of colorectal dysplasia is considered a strong predictor of CRC in IBD.190 Data not supportive of the benefit of surveillance colonoscopy may be due to missed lesions during the procedure. Newer endoscopy technologies may further improve
the sensitivity of dysplasia detection. The incorporation of high resolution video with methylene blue or indigo-carmine chromoendoscopy is superior to traditional random colonic biopsies in the detection rate of neoplastic lesions. The Korean data showing a high prevalence of CRC in longstanding
UC of 30 years may be reduced through greater awareness of colitis-associated CRC and regular screening.106 These are the first Asia-Pacific consensus statements on UC developed through a rigorous process of voting using the Delphi process and taking into account evidence from the current literature, regional data and input from a multi-disciplinary panel of experts belonging to the APAGE see more Working Group on IBD. Included in these statements for the first time are recommendations specific to the Asia-Pacific region with regards to testing of HBV and TB for patients considered for steroids, immunomodulators and biologic therapies. These statements were designed to harmonize definitions and provide recommendations in the diagnosis and management of an increasingly recognized disease in the Asia-Pacific. Differentiation of UC infectious colitis remains vital. Although available now for some time, biologic agents have not been used widely given their cost and risks in developing opportunistic infections such as TB. There is a need therefore to research this field further and develop guidelines on the use of chemoprophylactic treatments relevant to specific countries.